SRRKScholar Rock Holding Corp

Nasdaq scholarrock.com


$ 9.62 $ -0.35 (-3.46 %)    

Wednesday, 29-May-2024 13:15:15 EDT
QQQ $ 454.82 $ 1.40 (0.31 %)
DIA $ 398.57 $ -0.33 (-0.08 %)
SPY $ 530.36 $ 0.73 (0.14 %)
TLT $ 91.26 $ -0.49 (-0.55 %)
GLD $ 225.37 $ -1.73 (-0.79 %)
$ 10.33
$ 9.97
$ 9.60 x 100
$ 9.83 x 112
$ 9.62 - $ 10.02
$ 5.56 - $ 21.17
950,928
na
990.57M
$ -0.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-19-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-07-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-07-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-09-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-07-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-19-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 scholar-rock-presents-new-data-from-srk-181-phase-1-dragon-trial-at-the-asco-annual-meeting

- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/...

 hc-wainwright--co-reiterates-buy-on-scholar-rock-holding-maintains-30-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 ...

 hc-wainwright--co-reiterates-buy-on-scholar-rock-holding-maintains-30-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 ...

 scholar-rock-holding-q1-2024-gaap-eps-059-misses-051-estimate

Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate o...

 truist-securities-reiterates-buy-on-scholar-rock-holding-maintains-20-price-target

Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $20 pr...

 scholar-rock-is-a-potential-ma-target-its-exploration-of-obesity-market-garners-interest-analyst

Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of k...

 raymond-james-initiates-coverage-on-scholar-rock-holding-with-strong-buy-rating-announces-price-target-of-30

Raymond James analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy rating and ann...

 piper-sandler-maintains-overweight-on-scholar-rock-holding-maintains-28-price-target

Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and maintains $28 price...

 truist-securities-reiterates-buy-on-scholar-rock-holding-maintains-20-price-target

Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $20 pr...

 hc-wainwright--co-reiterates-buy-on-scholar-rock-holding-maintains-30-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 ...

 nio-reports-upbeat-earnings-joins-dave-v2x-riskified-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.

 scholar-rock-presents-new-preclinical-data-demonstrating-potential-benefit-of-srk-439-for-healthy-weight-loss-management

Preclinical findings presented at Keystone Symposia show lean mass preservation, fat mass loss, and improved glucose metabolism...

 scholar-rock-announces-presentation-of-new-preclinical-data-evaluating-srk-439-in-obesity-at-keystone-symposia

SRK-439 is a novel selective myostatin inhibitor designed for the treatment of cardiometabolic disordersPreclinical data suppor...

 scholar-rock-provides-2024-corporate-update-and-priorities

- Advancing industry-leading antimyostatin pipeline, comprised of multiple, novel assets with unparalleled selectivity, to trea...

 scholar-rock-holding-q3-2023-eps-053-misses-052-estimate

Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION